Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women

Mayo Clinic Proceedings

Volumn 88, Issue 1, 2013, Pages 46-55

  Peris, Pilar ^a,b   Atkinson, Elizabeth J ^a   Gössl, Mario ^a   Kane, Trevor L ^a   McCready, Louise K ^a   Lerman, Amir ^a   Khosla, Sundeep ^a   McGregor, Ulrike I ^a,c  

^a MAYO CLINIC   (United States)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CD133 ANTIGEN; CD34 ANTIGEN; FOLLITROPIN; INTERLEUKIN 8; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEONECTIN; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; VASCULOTROPIN RECEPTOR;

ARTICLE; BLOOD SAMPLING; BLOOD VESSEL CALCIFICATION; BONE TURNOVER; CD34 SELECTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; FOLLITROPIN BLOOD LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; NORMAL HUMAN; OSSIFICATION; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION;

EID: 84872977843     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.08.019     Document Type: Article

References (43)

1. Gossl M, Modder UI, Atkinson EJ, Lerman A, Khosla S. Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary artherosclerosis. J Am Coll Cardiol. 2008;52(16):1314-1325.
2. Gossl M, Modder UI, Gulati R, et al. Coronary endothelial dysfuntion in humans is associated with coronary retention of osteogenic endothelial progenitor cells. Eur Heart J. 2010; 31(23):2909-2914.
3. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stemlike cells. Nat Med. 2010;16(12):1400-1406.
4. Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition:potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293(1):L1-L8.
5. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H. Vascular calcification and osteoporosis: from clinical observation towards molecular understanding. Osteoporos Int. 2007;18(3):251-259.
6. Sambrook PN, Chen CJS, March LM, et al. High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res. 2006;21(4):549-555.
7. Chow JT, Khosla S, Melton LJI, Atkinson EJ, Camp JJ, Kearns AE. Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. J Bone Miner Res. 2008;23(10):1601-1612.
8. Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int. 2009;20(2):197-207.
9. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95(4):343-353.
10. Zampetaki A, Kirton JP, Wu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res. 2008;78(3):413-421.
11. Smith BJ, Lerner MR, Bu SY, et al. Systemic bone loss and induction of coronary vessell disease in a rat model of chronic inflammation. Bone. 2006;38(3):378-386.
12. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002; 30(9):973-981.
13. Chavakis E. IL-8: a new player in the homing of endothelial progenitor cells to ischemic myocardium. J Mol Cell Cardiol. 2006;40(4):442-445.
14. Skolnick AH, Osranek M, Formica P, Kronzon I. Osteoporosis treatment and progression of aortic stenosis. Am J Cardiol. 2009;104(1):122-124.
15. Koshiyama H, Nakamura Y, Tanaka S. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab. 2000;85(8):2793-2796.
16. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine. 2007;74(1):32-38.
17. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resportion. Arterioscler Thromb Vasc Biol. 2001;21(5):817-824.
18. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 2009;75(6):617-625.
19. Elmariah S, Delaney JA, O'Brien KD, et al. Bisphosphonate use and prevalence of valvular and vascular calcification in women: MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56(21):1752- 1759.
20. Luckish A, Cernes R, Boaz M, et al. Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors. Bone. 2008;43(2):279-283.
21. Neven EG, De Broe ME, D'Haese PC. Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int. 2009; 75(6):580-582.
22. Mödder UI, Roforth MM, Nicks KM, et al. Characterization of mesenchymal progenitor cells isolated from human bone marrow by negative selection. Bone. 2012;50(3):804-810.
23. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40(4):1079-1087.
24. Seibel MJ. Biochemical markers of bone turnover, part I: biochemistry and variability. Clin Biochem Rev. 2005;26(4):97-122.
25. Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Intern Med Res. 2009;37(2):407-416.
26. Reinholz GG, Betz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoclasts. Cancer Res. 2000;60(21):6001-6007.
27. Hamma-Koutbali Y, Benedetto M, Ledoux D, et al. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Comm. 2003; 310(3):816-823.
28. Yamada J, Tsuno NH, Kitayama J, et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res. 2009;151(1):115-120.
29. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999-1007.
30. Silvestre JS, Gojova A, Brun V, et al. Transplantation of bone marrow-derived mononuclear cells in ischemic apolipoprotein E-knockout mice accelerates atherosclerosis without altering plaque composition. Circulation. 2003; 108(23):2839-2842.
31. George J, Afek A, Abashidze A, et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2005;25(12):2636-2641.
32. Ziebart T, Pabst A, Klein MO, et al. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig. 2011;15(1):105-111.
33. Fadini GP, Albiero M, Menegazzo L, et al. Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. Circ Res. 2011;108(9):1112-1121.
34. Pirro M, Leli C, Fabbriciani G, et al. Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. Osteoporos Int. 2010;21(2):297-306.
35. Schulz E, Arfai K, Xiaodong L, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004;89(9):4246-4253.
36. Pirro M, Schillaci G, Mannarino MR, et al. Circulating immature osteoprogenitor cells and arterial stiffening in postmenopausal osteoporosis. Nutr Metab Cardiovasc Dis. 2011;21(9):636-642.
37. Gronthos S, Zannettino ACW, Graves SE, Ohta S, Hay SJ, Simmons PJ. Differential cell surface expression of the STRO 1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J Bone Miner Res. 1999;14(1):47-56.
38. Mahmoudi M, Curzen N, Gallagher PJ. Atherogenesis: the role of inflammation and infection. Histopatology. 2007;50(5):535-546.
39. Liehn EA, Zernecke A, Postea O, Weber C. Chemokines: inflammatory mediators of atherosclerosis. Arch Phys Biochem. 2006;112(4-5):229-238.
40. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol. 1998;27(1):38-41.
41. Dunn CJ, Galinet LA, Wu H, et al. Demonstration of a novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther. 1993;266(3):1691-1698.
42. Dundar U, Kavunku V, Ciftci IH, Evcik D, Solak O, Cajir T. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab. 2009;27(4):464-470.
43. Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol. 1999;26(11):2318-2323.